<p>Non-small cell lung cancer (NSCLC) constitutes a significant proportion of lung cancers and poses a serious threat to human health. Osimertinib is the first-line drug for treating NSCLC, but long-term use can lead to drug resistance. Exploring the mechanism of drug resistance and effectively selecting treatment plans based on the mechanism of resistance are urgent issues to be addressed. In this study, dryness characteristics were evaluated by measuring cell activity, cell spheroid formation and cloning conditions, and the levels of stem cell marker molecules. The sensitivity of SPP1 to osimertinib was also assessed in mice. The results showed that SPP1 regulates cancer stem cells (CSCs) by interacting with CD44, thereby generating osimertinib resistance. These findings provide a basis for clinical research.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

SPP1 promotes cancer stemness and reduces osimertinib sensitivity in non-small cell lung cancer through interactions with CD44

  • Hong Bi,
  • Lewei He,
  • Liyan Wang,
  • Lijuan Yang,
  • Jing Shao,
  • Hang Li,
  • Xiang Guo,
  • Hong Liu,
  • Yaping Fu,
  • Huiming Wang,
  • Yue Wang,
  • Zhixian Jin,
  • Min Chen

摘要

Non-small cell lung cancer (NSCLC) constitutes a significant proportion of lung cancers and poses a serious threat to human health. Osimertinib is the first-line drug for treating NSCLC, but long-term use can lead to drug resistance. Exploring the mechanism of drug resistance and effectively selecting treatment plans based on the mechanism of resistance are urgent issues to be addressed. In this study, dryness characteristics were evaluated by measuring cell activity, cell spheroid formation and cloning conditions, and the levels of stem cell marker molecules. The sensitivity of SPP1 to osimertinib was also assessed in mice. The results showed that SPP1 regulates cancer stem cells (CSCs) by interacting with CD44, thereby generating osimertinib resistance. These findings provide a basis for clinical research.